nach oben

Erschienen in:

27.08.2019 | Ernährung | zertifizierte fortbildung

Ernährung bei Diabetes und Fettleber

Das Leben und das Essen trotz nichtalkoholischer Fettleber genießen

verfasst von: Prof. Dr. med. Jörg Bojunga, Dr. med. Gesine Meyer, Dr. med. Antonia Mondorf

Erschienen in: Info Diabetologie | Ausgabe 4/2019

Einloggen, um Zugang zu erhalten

Zusammenfassung

Steigende Inzidenzen von nichtalkoholischer Fettlebererkrankung (NAFLD) und Diabetes mellitus Typ 2 erfordern Aufmerksamkeit für die Zusammenhänge beider Erkrankungen und das sollte bei Betroffenen diagnostische und therapeutische Interventionen nach sich ziehen. Allem voran stehen Lebensstilmaßnahmen. Erfreulich: Die bei NAFLD empfohlene mediterrane Ernährung lässt auch noch viel Raum für den Genuss.

Roeb, E. et al. [S2k Guideline non-alcoholic fatty liver disease]. Zeitschrift für Gastroenterol. 53, 668–723 (2015).CrossRef

Younossi, Z. M. et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64, 73–84 (2016).CrossRef

Jacobs, E., Hoyer, A., Brinks, R., Kuss, O. & Rathmann, W. Burden of Mortality Attributable to Diagnosed Diabetes: A Nationwide Analysis Based on Claims Data From 65 Million People in Germany. Diabetes Care 40, 1703–1709 (2017).CrossRefPubMed

Lonardo, A., Nascimbeni, F., Mantovani, A. & Targher, G. Hypertension, diabetes, atherosclerosis and NASH: Cause or consequence? J. Hepatol. 68, 335–352 (2018).CrossRefPubMed

Goldberg, D. et al. Changes in the Prevalence of Hepatitis C Virus Infection, Nonalcoholic Steatohepatitis, and Alcoholic Liver Disease Among Patients With Cirrhosis or Liver Failure on the Waitlist for Liver Transplantation. Gastroenterology 152, 1090–1099.e1 (2017).CrossRefPubMedPubMedCentral

Utz-Melere, M. et al. Non-Alcoholic Fatty Liver Disease in Children and Adolescents: Lifestyle Change - a Systematic Review and Meta-Analysis. Ann. Hepatol. 17, 345–354 (2018).CrossRefPubMed

Romero-Gomez, M., Zelber-Sagi, S. & Trenell, M. Treatment of NAFLD with diet, physical activity and exercise. J. Hepatol. 67, 829–846 (2017).CrossRefPubMed

Mummadi, R. R., Kasturi, K. S., Chennareddygari, S. & Sood, G. K. Effect of Bariatric Surgery on Nonalcoholic Fatty Liver Disease: Systematic Review and Meta-Analysis. Clin. Gastroenterol. Hepatol. 6, 1396–1402 (2008).CrossRefPubMed

Plauth, M. et al. ESPEN guideline on clinical nutrition in liver disease. (2018). doi:10.1016/j.clnu.2018.12.022CrossRefPubMed

10.

Roeb, E. et al. S2k-Leitlinie nicht alkoholische Fettlebererkrankungen AWMF Register Nr. 021-025 Version Januar 2015, Erstauflage. Z. Gastroenterol. 53, 668–723 (2015).CrossRefPubMed

11.

Grontved, A. & Hu, F. B. Television Viewing and Risk of Type 2 Diabetes, Cardiovascular Disease, and All-Cause Mortality A Meta-analysis. JAMA 305, 2448–2455 (2011).

12.

Hashida, R. et al. Aerobic vs. resistance exercise in non-alcoholic fatty liver disease: A systematic review. J. Hepatol. 66, 142–152 (2017).CrossRefPubMed

13.

Stewart, K. E. et al. Readiness for behaviour change in non-alcoholic fatty liver disease: implications for multidisciplinary care models. Liver Int. 35, 936–943 (2015).CrossRefPubMed

14.

Pugh, C. J. A. et al. Exercise-induced improvements in liver fat and endothelial function are not sustained 12 months following cessation of exercise supervision in nonalcoholic fatty liver disease. Int. J. Obes. 40, 1927–1930 (2016).CrossRefPubMed

15.

Kechagias, S. et al. Fast-food-based hyper-alimentation can induce rapid and profound elevation of serum alanine aminotransferase in healthy subjects. Gut 57, 649–654 (2008).CrossRefPubMedPubMedCentral

16.

Davies, M. J. et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 61, 2461–2498 (2018)).CrossRef

17.

Hyde, P. N. et al. Dietary carbohydrate restriction improves metabolic syndrome independent of weight loss. JCI Insight 4, (2019).

18.

Gepner, Y. et al. Effect of Distinct Lifestyle Interventions on Mobilization of Fat Storage Pools: The CENTRAL MRI Randomized Controlled Trial. Circulation CIRCULATIONAHA.117.030501 (2017). doi:10.1161/CIRCULATIONAHA.117.030501CrossRefPubMed

19.

Shai, I. et al. Weight loss with a low-carbohydrate, Mediterranean, or low-fat diet. N. Engl. J. Med. 359, 229–41 (2008).CrossRefPubMed

20.

Bach-Faig, A. et al. Mediterranean diet pyramid today. Science and cultural updates. Public Health Nutr. 14, 2274–2284 (2011).CrossRefPubMed

21.

Kastorini, C.-M. et al. The effect of Mediterranean diet on metabolic syndrome and its components: a meta-analysis of 50 studies and 534,906 individuals. J. Am. Coll. Cardiol. 57, 1299–313 (2011).CrossRefPubMed

22.

Ryan, M. C. et al. The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease. J. Hepatol. 59, 138–43 (2013).CrossRefPubMed

23.

Trovato, F. M., Catalano, D., Martines, G. F., Pace, P. & Trovato, G. M. Mediterranean diet and non-alcoholic fatty liver disease. The need of extended and comprehensive interventions. Clin. Nutr. 34, 86–88 (2015).CrossRefPubMed

24.

Ma, J. et al. Improved Diet Quality Associates With Reduction in Liver Fat, Particularly in Individuals With High Genetic Risk Scores for Nonalcoholic Fatty Liver Disease. Gastroenterology 155, 107–117 (2018).CrossRefPubMedPubMedCentral

25.

Azais-Braesco, V., Sluik, D., Maillot, M., Kok, F. & Moreno, L. A. A review of total & added sugar intakes and dietary sources in Europe. Nutr. J. 16, 6 (2017).CrossRefPubMedPubMedCentral

26.

Morenga, L. Te, Mallard, S. & Mann, J. Dietary sugars and body weight: systematic review and meta-analyses of randomised controlled trials and cohort studies. BMJ 346, e7492 (2013).CrossRef

27.

Yang, Q. et al. Added Sugar Intake and Cardiovascular Diseases Mortality Among US Adults. JAMA Intern. Med. 174, 516 (2014).CrossRefPubMed

28.

Bundesinstitut fur Risikobewertung. Erhohte Aufnahme von Fruktose ist fur Diabetiker nicht empfehlenswert. (2009).

29.

Ouyang, X. et al. Fructose consumption as a risk factor for non-alcoholic fatty liver disease. J. Hepatol. 48, 993–9 (2008).CrossRefPubMedPubMedCentral

30.

Abdelmalek, M. F. et al. Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease. Hepatology 51, 1961–71 (2010).CrossRefPubMedPubMedCentral

31.

Jegatheesan, P. & De Bandt, J. P. Fructose and NAFLD: The multifaceted aspects of fructose metabolism. Nutrients 9, 1–13 (2017).CrossRef

32.

Lustig, R. H. Fructose: It‘s „Alcohol Without the Buzz“. Adv. Nutr. 4, 226–235 (2013).CrossRefPubMedPubMedCentral

33.

Giannelli, V. et al. Microbiota and the gut-liver axis: Bacterial translocation, inflammation and infection in cirrhosis. World Journal of Gastroenterology 20, 16795–16810 (2014).CrossRefPubMedPubMedCentral

34.

Meyers, A. M., Mourra, D. & Beeler, J. A. High fructose corn syrup induces metabolic dysregulation and altered dopamine signaling in the absence of obesity. PLoS One 12, e0190206 (2017).CrossRefPubMedPubMedCentral

35.

Guideline: Sugars Intake for Adults and Children. Guideline: Sugars Intake for Adults and Children (World Health Organization, 2015).

36.

Chiu, S. et al. Effect of fructose on markers of non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of controlled feeding trials. Eur. J. Clin. Nutr. 68, 416.23 (2014).CrossRefPubMedPubMedCentral

37.

Dunn, W. et al. Modest alcohol consumption is associated with decreased prevalence of steatohepatitis in patients with non-alcoholic fatty liver disease (NAFLD). J. Hepatol. 57, 384–391 (2012).CrossRefPubMedPubMedCentral

38.

Hajifathalian, K., Torabi Sagvand, B. & McCullough, A. J. Effect of Alcohol Consumption on Survival in Nonalcoholic Fatty Liver Disease: A National Prospective Cohort Study. Hepatology (2018). doi:10.1002/hep.30226CrossRefPubMed

39.

Ascha, M. S. et al. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 51, 1972–1978 (2010).CrossRefPubMed

40.

George, E. S. et al. Practical Dietary Recommendations for the Prevention and Management of Nonalcoholic Fatty Liver Disease in Adults. Adv. Nutr. 9, 30–40 (2018).CrossRefPubMedPubMedCentral

41.

Allard, J. P. et al. Nutritional assessment and hepatic fatty acid composition in non-alcoholic fatty liver disease (NAFLD): A cross-sectional study. J. Hepatol. 48, 300–307 (2008).CrossRefPubMed

42.

Scorletti, E. et al. Effects of purified eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver disease: Results from the WELCOME* study. Hepatology 60, 1211–1221 (2014).CrossRef

43.

Sanyal, A. J., Abdelmalek, M. F., Suzuki, A., Cummings, O. W. & Chojkier, M. No Significant Effects of Ethyl-Eicosapentanoic Acid on Histologic Features of Nonalcoholic Steatohepatitis in a Phase 2 Trial. Gastroenterology 147, 377–384.e1 (2014).CrossRefPubMed

44.

Musa-Veloso, K. et al. Systematic review and meta-analysis of controlled intervention studies on the effectiveness of long-chain omega-3 fatty acids in patients with nonalcoholic fatty liver disease. Nutr. Rev. 76, 581–602 (2018).CrossRefPubMedPubMedCentral

45.

Molloy, J. W. et al. Association of coffee and caffeine consumption with fatty liver disease, nonalcoholic steatohepatitis, and degree of hepatic fibrosis. Hepatology 55, 429–36 (2012).CrossRefPubMed

46.

Birerdinc, A., Stepanova, M., Pawloski, L. & Younossi, Z. M. Caffeine is protective in patients with non-alcoholic fatty liver disease. Aliment. Pharmacol. Ther. 35, 76–82 (2012).CrossRefPubMed

47.

Kennedy, O. J. et al. Coffee, including caffeinated and decaffeinated coffee, and the risk of hepatocellular carcinoma: a systematic review and dose-response meta-analysis. BMJ Open 7, e013739 (2017).CrossRefPubMedPubMedCentral

48.

Yesil, A. & Yilmaz, Y. Review article: coffee consumption, the metabolic syndrome and non-alcoholic fatty liver disease. Aliment. Pharmacol. Ther. 38, 1038–44 (2013).CrossRefPubMed

49.

Ikram, M. A. et al. The Rotterdam Study: 2018 update on objectives, design and main results. Eur. J. Epidemiol. 32

50.

Zelber-Sagi, S. et al. High red and processed meat consumption is associated with non-alcoholic fatty liver disease and insulin resistance. J. Hezertifizierte patol. 68, 1239–1246 (2018).

51.

Kani, A. H., Alavian, S. M., Esmaillzadeh, A., Adibi, P. & Azadbakht, L. Effects of a novel therapeutic diet on liver enzymes and coagulating factors in patients with non-alcoholic fatty liver disease: A parallel randomized trial. Nutrition 30, 814–821 (2014).CrossRefPubMed

52.

Lean, M. E. et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. Lancet 391, 541–551 (2018).CrossRefPubMed

53.

Diabetes (Taylor, R. et al. Remission of Human Type 2 Diabetes Requires Decrease in Liver and Pancreas Fat Content but Is Dependent upon Capacity for β Cell Recovery. Cell Metab. 28, 667 (2018)

54.

Cheskin, L. J. et al. Efficacy of meal replacements versus a standard food-based diet for weight loss in type 2 diabetes: a controlled clinical trial. Diabetes Educ. 34, 118–27 (2008).CrossRefPubMed

55.

Oko-Test Ausgabe 2/16 (2016), S 46–53

56.

Bojunga, J. & Sircar, I. Formuladiaten zum Abnehmen bei Typ-2-Diabetes. sinnvolle Strategie oder verzichtbar? Der Diabetol.} 13, 398–402 (2017).CrossRef

57.

Kasmari, A. J. et al. Independent of Cirrhosis, Hepatocellular Carcinoma Risk Is Increased with Diabetes and Metabolic Syndrome. Am. J. Med. (2017). doi:10.1016/j.amjmed.2016.12.029

58.

Iranshahy, M., Rezaee, R. & Karimi, G. Hepatoprotective activity of metformin: A new mission for an old drug? Eur. J. Pharmacol. 850, 1.7 (2019).

59.

Joy, T. R. et al. Sitagliptin in patients with non-alcoholic steatohepatitis: A randomized, placebo-controlled trial. World J. Gastroenterol. 23, 141.150 (2017).CrossRefPubMedPubMedCentral

60.

Cui, J. et al. Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial. J. Hepatol. 65, 369–376 (2016).CrossRefPubMedPubMedCentral

61.

Armstrong, M. J. et al. Glucagon-Like Peptide 1 Decreases Lipotoxicity in Non-Alcoholic Steatophepatitis. J. Hepatol. 64, 399–408 (2015).CrossRefPubMed

62.

Armstrong, M. J. et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet (London, England) 387, 679–90 (2015).CrossRef

63.

Eriksson, J. W. et al. Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study. Diabetologia 61, 1923–1934 (2018).CrossRefPubMedPubMedCentral

64.

Murdoch, C., Unwin, D., Cavan, D., Cucuzzella, M. & Patel, M. Adapting diabetes medication for low carbohydrate management of type 2 diabetes: a practical guide. Br. J. Gen. Pract. 69, 360–361 (2019).CrossRefPubMedPubMedCentral

65.

Pose, E., Trebicka, J., Mookerjee, R. P., Angeli, P. & Gines, P. Statins: Old drugs as new therapy for liver diseases? J. Hepatol. 70, 194–202 (2019).CrossRefPubMed

66.

Kim, G., Jang, S.-Y., Nam, C. M. & Kang, E. S. Statin use and the risk of hepatocellular carcinoma in patients at high risk: A nationwide nested case-control study. J. Hepatol. (2017). doi:10.1016/j.jhep.2017.10.018CrossRefPubMed

67.

Del Ben, M. et al. Under-prescription of statins in patients with non-alcoholic fatty liver disease. Nutr. Metab. Cardiovasc. Dis. 27, 161–167 (2017).

68.

Pastori, D. et al. The efficacy and safety of statins for the treatment of non-alcoholic fatty liver disease. Dig. Liver Dis. 47, 4–11 (2015).CrossRefPubMed

69.

Hirose, A. et al. Angiotensin II type 1 receptor blocker inhibits fibrosis in rat nonalcoholic steatohepatitis. Hepatology 45, 1375–1381 (2007).CrossRefPubMed

70.

Simon, T. G. et al. Association Between Aspirin Use and Risk of Hepatocellular Carcinoma. JAMA Oncol. 4, 1683 (2018).CrossRefPubMed

Titel: Ernährung bei Diabetes und Fettleber
Das Leben und das Essen trotz nichtalkoholischer Fettleber genießen
verfasst von: Prof. Dr. med. Jörg Bojunga
Dr. med. Gesine Meyer
Dr. med. Antonia Mondorf
Publikationsdatum: 27.08.2019
Verlag: Springer Medizin
Schlagwörter: Ernährung
Fettleber
Erschienen in: Info Diabetologie / Ausgabe 4/2019
Print ISSN: 1865-5459
Elektronische ISSN: 2196-6362
DOI: https://doi.org/10.1007/s15034-019-1527-1

Passend zum Thema

Fatal verkannt: Vitamin-B12-Mangel frühzeitig behandeln!

Ernährung

Müdigkeit und Erschöpfung sind meist die ersten Symptome eines Vitamin-B12-Mangels. Wird das Defizit nicht rechtzeitig behandelt, drohen mitunter schwerwiegende Folgen. Lesen Sie hier, was bei der Therapie zu beachten ist.

Vitamin-B12-Mangel durch Arzneimittel

Ernährung

Einige häufig verordnete Medikamente wie das orale Antidiabetikum Metformin oder Protonenpumpeninhibitoren (PPI) können einen Mangel an Vitamin B12 verursachen. Bei einer Langzeitmedikation mit diesen Wirkstoffen sollte daher an ein mögliches Defizit gedacht werden. Erfahren Sie hier, worauf dabei zu achten ist.

Vitamin-B12-Mangel – Aktuelles Basiswissen für die Praxis.

Content Hub

Ein Mangel an Vitamin B12 tritt in bestimmten Risikogruppen häufig auf. Diese Patienten sind auch regelmäßig in Ihrer Praxis. Wird der Mangel nicht rechtzeitig behandelt, drohen mitunter schwerwiegende Folgen. Erhalten Sie hier einen Überblick über aktuelles Basiswissen für den Praxisalltag.

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2019

Speisepilz —keine Wunderwaffe gegen Diabetes

Auf ins Abenteuer Digitalisierung — aber mit System

Schwangere mit Antipsychotikatherapie haben erhöhtes Risiko für Gestationsdiabetes

Alternativ zur Injektion: Orale Dreifachkombi

Nonverbale Kommunikation ist ein mächtiges Instrument

Schwere Stoffwechselentgleisung mit Folgen — durch „kleines“ Versäumnis

Passend zum Thema

Fatal verkannt: Vitamin-B12-Mangel frühzeitig behandeln!

Vitamin-B12-Mangel durch Arzneimittel

Vitamin-B12-Mangel – Aktuelles Basiswissen für die Praxis.